AI Platform Empowering Next-Gen Drug Discovery & Development

PharmetRx Engine

Scroll Down ⇩
Request QuoteLearn More


PharmetRx® is a novel, computational drug discovery and development platform that uses artificial intelligence to collect and integrate biological, chemical, and human clinical data to discover promising new drug candidates, de-risk product opportunities through pre-clinical studies, and validate drugs in early clinical proof of concept studies.


^Our approach is proven to increase ROI through risk reduction and time and cost savings.


The first drug developed with PharmetRx® was licensed to Supernus (NASDAQ: SUPN) and was granted fast-track approval by the FDA and is currently in a final, Phase III clinical trial.


Step #1

We work with chemical and biological data to validate lead compounds

Read More


Step #2

We provide de-risked lead compounds & derivative compound libraries

More Info


Step #3

We create novel IP based around diseases, drug targets, & compounds

See an example

Step #4

We accelerate your drug program with preclinical “IND-ready” data packages

Reach Out For More Info

Our Satisfied Clients

Download our slide deck to view featured case studies:

Management Team


Driven • Experienced • Focused • Reliable

Bruce Kovacs, MD
Chief Executive Officer

Dr. Kovacs is a co-founder of PharmetRx and inventor of a key molecular genetic technology and other biometrics that are integrated into the PharmetRx technology platform. Bruce was Clinical Professor and Director of the Molecular & Cytogenetics Laboratory at the Keck School of Medicine at USC for over 20 years. He developed several technologies for analysis of DNA/RNA for the purposes of disease diagnosis, drug discovery, and human identification. He has served as a consultant to the U.S. Department of Justice, FBI, and other government agencies in the areas of molecular diagnostics and forensic identification. Dr. Kovacs received his M.D. from the Keck School of Medicine at the University of Southern California.

Hal Lieberman, MHA
Chief Operating Officer

Mr. Lieberman has more than thirty years of experience in healthcare management, including medical devices, pharmaceuticals and health care services. Hal is the former CEO of HemaCare Corporation. His other management experience includes the development of an immune therapy for AIDS, and partnerships with Squibb, Novartis and GlaxoSmithKline. He has served on the board of directors of Atopix Pharmaceuticals, BioDiscovery, Inc., ALine, Inc., and the Pacific Heart, Lung, and Blood Institute. Mr. Lieberman earned a master's degree in healthcare administration from The George Washington University, and is a member of the American College of Healthcare Executives.

Peter Blaisdell, PhD
VP, Clinical Development

Dr. Blaisdell leads clinical development for client drug programs at PharmetRx. In his previous role, he was the Executive Director of Global Study Management at Amgen. He joined Amgen in 1998 supporting clinical research programs in infectious disease and nephrology and supporting the design and conduct of global cardiovascular and nephrology outcomes trials, successfully executing international phase 2 and 3 trials in support of filings, as well as phase 4 trials providing post-marketing support for a variety of therapies. He holds a Ph.D. in Biochemistry from the University of Minnesota, and a BS from the University of Michigan.


Our Offices

2102 Business Center Dr
Irvine, CA 92612
12636 High Bluff Dr #400
San Diego, CA 92130


Let us know how we can help you






PharmetRx, LLC is a specialty, contract research organization offering a more efficient path to drug discovery, clinical development, and regulatory approval.


Our vision is to be the go-to industry leader for helping pharmaceutical companies avoid disheartening and expensive setbacks related to Phase II clinical trial failures, adverse side effects, or unsuspected toxicities.


In the early days, PharmetRx worked with physician-scientists at the University of Southern California, City of Hope/Beckman Research Institute, University of California Irvine, and the California Institute of Technology, to study the role of genetics and the actions of drugs on human diseases. Initial research efforts focused on correlations between the underlying genetic differences among different patient groups and their differential drug-responses. With the insights that followed, we set to de-convolute the symptoms and uncover the underlying mechanisms of diseases from which these patients suffered. The resulting approach allowed us to then develop novel methods and a comprehensive drug discovery platform, PharmetRx®, to classify diseases, sub-type patient groups, identify key disease pathways, and discover new drugs that were safer and more effective. The first drug developed with PharmetRx® was licensed to Supernus (NASDAQ: SUPN) and was granted fast-track approval by the FDA and is currently in a final, Phase III clinical trial.